RxDoctor Payments Data

Mandip Kang, MD

Nephrology · Peoria, AZNPI 1023002946

Payments from drug & device makers

$1,036in general payments, 2019–2025

Across 43 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$182
  • Vantive US Healthcare LLC$128
  • Bayer$120
  • AstraZeneca$118
  • UCB, Inc.$98
  • Akebia Therapeutics Inc$85
  • plus $305 from 8 others

What the payments were for

  • Food & beverage$1,01698%
  • Education$212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,036 in reported general payments places this provider in the 30th percentile of 259 nephrology providers in Arizona.

See all nephrology providers in Arizona

Medicare billing

Part B allowed, 2024
$474,897
Medicare patients
661
Services billed
16,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl90$273,300
FarxigaDapagliflozin Propanediol197$198,912
LokelmaSodium Zirconium Cyclosilicate75$66,252
VeltassaPatiromer Calcium Sorbitex18$31,733
JardianceEmpagliflozin29$19,635
Sevelamer Carbonate98$15,226
Calcitriol531$11,591
Calcium Acetate57$5,489
Nifedipine ErNifedipine142$5,189
Allopurinol264$4,172
ProsolParenteral Amino Acid 20% No.125$4,101
Potassium Citrate ErPotassium Citrate24$3,364
Doxazosin Mesylate195$2,703
Famotidine173$2,509
Bumetanide61$2,210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$118$265,164272 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 259 nephrology providers in Arizona.

Other nephrology in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →